Hong Kong-listed biotechnology companies have seen a rise in stock prices following Moderna’s success with a cancer vaccine trial, prompting several Chinese firms to advance their own vaccine developments. These companies, including Jiangsu Hengrui Pharmaceuticals and CK Life Sciences, are part of a burgeoning pipeline of over 100 cancer vaccine projects in China. However, experts note that the major challenge will be extending the breakthrough beyond melanoma, as its market potential is limited. Additionally, the feasibility of producing personalized vaccines efficiently and affordably remains uncertain.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.scmp.com/business/china-business/article/3365261/china-rushes-develop-moderna-style-cancer-vaccines-amid-market-frenzy
